Mortality reductions produced by sustained Prostate Cancer screening have been underestimated

22Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: The recently published European Randomized Study of Screening for Prostate Cancer (ERSPC) reported prostate specific antigen (PSA)-based screening to have reduced the prostate cancer death rate by only 20%. However, this is an underestimate caused by (i) including in the 20% the years before the impact of the first screen becomes manifest, and (ii) not having full information for the followup years where the effects of the screening are most apparent. This paper provides a re-analysis of the results using time-specific measures, which avoid the first of these sources of error. Methods: Mortality rate ratios for follow-up years 1-12 were derived from the yearly numbers of prostate cancer deaths and numbers of men being followed in each arm of the ERSPC. To reduce statistical noise, they were based on moving three-year intervals, and a smooth rate ratio curve was fitted to the yearly data, in order to measure the steady state reduction in mortality and to identify the time at which it reached this level. Results: The re-analysis suggests that the sustained reduction in prostate cancer mortality may be more than 50%. Conclusion: Re-analysis of the ERSPC data suggests that if screening is carried out for several years, and if follow-up is pursued until the reduction becomes manifest, the reduction in mortality will be 50- 60%. An analysis that includes the 2007-2008 follow-up data is required to quantify more precisely the impact of this intervention.

References Powered by Scopus

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

5841Citations
N/AReaders
Get full text

Screening and prostate-cancer mortality in a randomized european study

3450Citations
N/AReaders
Get full text

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

2607Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Potent anti-cancer effects of citrus peel flavonoids in human prostate xenograft tumors

71Citations
N/AReaders
Get full text

Limitations of basing screening policies on screening trials: The US preventive services task force and prostate cancer screening

68Citations
N/AReaders
Get full text

Assessment of lung-cancer mortality reduction from CT Screening

65Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Hanley, J. A. (2010). Mortality reductions produced by sustained Prostate Cancer screening have been underestimated. Journal of Medical Screening, 17(3), 147–151. https://doi.org/10.1258/jms.2010.010005

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 6

60%

Researcher 3

30%

Professor / Associate Prof. 1

10%

Readers' Discipline

Tooltip

Medicine and Dentistry 4

40%

Social Sciences 3

30%

Computer Science 2

20%

Nursing and Health Professions 1

10%

Save time finding and organizing research with Mendeley

Sign up for free